Robert Lieberman, MD
Dermatology · Henderson, NVNPI 1639308943
Payments from drug & device makers
Across 474 payments — averaging $55.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Biofrontera Inc.$6K
- Regeneron$5K
- AbbVie$2K
- Johnson & Johnson$1K
- Merz North America, Inc.$957
- plus $5K from 25 others
What the payments were for
- Speaking & faculty fees$10,57549%
- Travel & lodging$9084%
- Food & beverage$9,27043%
- Education$9354%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 42 | $6,983 |
| Biofrontera Inc. | 11 | $5,754 |
| Regeneron | 7 | $4,529 |
| AbbVie | 112 | $1,871 |
| Johnson & Johnson | 39 | $1,145 |
| Merz North America, Inc. | 7 | $957 |
| Sanofi | 41 | $697 |
| Novartis | 28 | $667 |
| Sun Pharmaceutical Industries Inc. | 38 | $653 |
| LEO Pharma Inc. | 24 | $426 |
| Galderma Laboratories, L.p. | 23 | $351 |
| UCB, Inc. | 8 | $304 |
| Amgen | 13 | $273 |
| Boehringer Ingelheim | 9 | $222 |
| Regeneron Healthcare Solutions, Inc. | 9 | $210 |
| Sanofi-aventis U.S. LLC | 4 | $200 |
| Arcutis Biotherapeutics, Inc. | 17 | $197 |
| Genentech USA, Inc. | 14 | $186 |
| Aclaris Therapeutics, Inc. | 1 | $119 |
| Incyte Corporation | 6 | $99 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $54 |
| Almirall LLC | 3 | $50 |
| Dermavant Sciences, Inc. | 3 | $47 |
| Botanix SB Inc | 2 | $43 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Bristol Myers Squibb | 2 | $35 |
| Dermira, Inc. | 1 | $33 |
| Lilly USA, LLC | 1 | $26 |
| Organon | 2 | $22 |
| Mayne Pharma Commercial LLC | 1 | $18 |
| EPI Health, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$6,301
- AMELUZ$5,696
- BF-RhodoLED$5,696
- XEPI$5,696
- XEOMIN$300
- Bimzelx$130
- Rhofade$119
- EPIDUO FORTE$104
How this compares
$26,217 in reported general payments places this provider in the 85th percentile of 78 dermatology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 14 | $306,405 |
| Dupixent PenDupilumab | 52 | $263,724 |
| Clobetasol Propionate | 124 | $4,611 |
| Fluorouracil | 47 | $2,956 |
| Ketoconazole | 155 | $2,815 |
| Acyclovir | 15 | $2,157 |
| Triamcinolone Acetonide | 202 | $1,684 |
| Imiquimod | 46 | $1,004 |
| Doxycycline Hyclate | 61 | $997 |
| Clindamycin Phosphate | 22 | $923 |
| Metronidazole | 22 | $874 |
| ValacyclovirValacyclovir Hcl | 43 | $714 |
| Mupirocin | 100 | $707 |
| CiclopiroxCiclopirox Olamine | 26 | $686 |
| Mometasone Furoate | 26 | $593 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Henderson
- Curt SamlaskaHenderson$101K
- Juian-Juian FuHenderson$12K
- Cristian GonzalezHenderson$3K
- Daniel XieHenderson$2K
- Harry GreenbergLas Vegas$1.5M
- David CotterLas Vegas$1.5M
- Victoria FarleyLas Vegas$956K
- Miriam BettencourtLas Vegas$772K
- James SolomonNorth Las Vegas$733K
- Irene ManneringSparks$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.